The Society for Immunotherapy of Cancer is pleased to share a collaborative effort between the HHS Assistant Secretary for Technology Policy/Office of the National Coordinator for Health Information Technology (ASTP), the National Cancer Institute (NCI), and Food and Drug Administration (FDA) focused on the release of the USCDI+ Cancer Immune-related Adverse Events (irAE) draft dataset. The goal of this data set is to enhance the accuracy and reliability of detecting signals for immune-related adverse events using real-world data.
An open comment period on the draft data set is now available through January 10th, 2025. More information regarding the dataset, requested comment topics, as well as instructions for submitting comment are available at this LINK. SITC encourages participation and any individuals or organizations with questions regarding the dataset or submitting comment should contact USCDI.plus@hhs.gov.